Reconfigurable Radio System Test bed for security research

Technological progress on the digital processing has opened the way to a novel implementation approach for wireless communication platforms where most of the digital signal processing is done in software rather than in hardware. Such systems have been known as Software Defined Radio (SDR) or Reconfigurable Radio Systems (RRS). A typical SDR/RRS is able to execute all the radio frequency and base-band processing though software components rather then hardware components as in conventional radio communication systems. This capability provides a high level of reconfigurability and the possibility to implement a number of different algorithms for digital processing. Therefore, SDR/RRS can be used for a variety or purposes including the possibility of implementing wireless security attacks against conventional communication systems. In this technical report, we present an application of the SDR/RRS platform to implement a security attack against a DECT platform. The SDR/RRS platform has been used to implement a DECT demodulator and a processing module to eavesdrop and capture user and control data transmitted by a DECT system. The commercially available Universal Software Radio Peripheral (USRP) has been used as SDR/RRS platform for the development of the prototype. The paper presents the technical challenges and implementation details in the development of the prototype and an overview of the capabilities of the USRP to implement wireless security attacks. The SDR/RRS platform used in the project is quite versatile and it can be used for a number of other applications related to DECT or other wireless communication systems.JRC.G.6-Security technology assessmen

Proof of Concept (PoC) of the remote interrogation for the smart tachograph based on CEN-Dedicated Short Range Communications (DSRC)

The aim of this technical report is to describe the proof-of-concept of the CEN-DSRC imple- mentation of the remote interrogation function of the new version of the digital tachograph. The current digital tachograph (DT) system to monitor the driving time in commercial ve- hicles above 3.5 tons is governed by Council Regulation (EEC) No 3821/85 of 20 December 1985, which was modified at several occasions and more recently in 2006, when the digital tachograph was introduced, and in 2009, when it was updated to technical progress to avoid fraud and reduce the administrative burden. In July 2011 the Commission made a proposal (COM(2011) 451 final) to modify the tachograph regulation, which has been the object of discussions in Council and Parliament in the course of the ordinary legislative procedure. The final version of the approved regulation was published in February 2014 (Regulation 165/2014 (Commission, 2004)). The technical specifications of the smart tachograph were published as Regulation 799/2016 (Commission, 2011). One of the main functions is the remote interrogation of the Smart Tachograph (ST) installed in the commercial vehicle through the CEN-DSRC standard. The function supports law enforcers in the checking of potential frauds or malfunctions in the ST. To support the future deployment of the smart tachograph and to validate the technical specifications of the smart tachograph regarding the remote interrogation function, JRC issued a tender to the DSRC manufacturer Q-FREE to implement a prototype of the new remote interrogation systems. The prototype was successfully implemented and tested. It was shown during the JRC Open day in May 2016 to thousands of visitors at the stand of the smart tachograph organized by unit DG.JRC.E3.JRC.E.3-Cyber and Digital Citizens' Securit

Passive Automatic Identification System for Maritime Surveillance

This work describes the main achievements in the Passive AIS (P-AIS) project stage. The extensive literature research in the second chapter concludes performing additional in-situ experiments to estimate reliable target RCS and clutter reflectivity values at the AIS frequency range. The typical effective RCS distribution for ferry, yacht and small wooden boat is experimentally drawn; it reaches up to 26dBsm for the ferry. A clutter model is created, taking into account the literature and the experimental study. The AIS signal waveform is analyzed and the potential range and Doppler resolution is defined. More specifically, the signal ambiguity function gives approximately 20km of range resolution and 40Hz Doppler resolution. A coverage prediction tool, based on the bistatic radar equation, including the aforementioned clutter model; bistatic geometry theory; the effective target RCS; the antenna pattern; the AIS air interface parameters is made. The tool estimates the possible P-AIS coverage area. The work concludes that: even in case of high sea state, the sea is considered as a smooth surface reflection for low grazing angle of observation in the VHF range; the equidistant SNR areas change from Cassini shape to single oval receiver centered; the AIS energy provides excellent target “visibility” if the clutter is not considered. Discussions for further clutter reduction and system sophistication are arisen.JRC.G.4-Maritime affair

Blockchain in Energy Communities, A proof of concept

This report aims at exploring the use of the distributed ledger paradigm to incentive the participation of the citizen to a truly free, open and interoperable energy market, producing a feasibility study and a first demo testbed, taking also into consideration privacy, cybersecurity and big-data issues of the smart-home in the Energy market context. This study is intended to support point 4.1, 4.2 and 4.3 of the DSM (COM(2015)192) and point 2.2 of the Energy Union package (COM(2015)80.JRC.E.3-Cyber and Digital Citizens' Securit

Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis

Background: Multiple myeloma (MM) is a clonal plasma cell malignancy associated with osteolytic bone disease. Recently, the role of MM-derived exosomes in the osteoclastogenesis has been demonstrated although the underlying mechanism is still unknown. Since exosomes-derived epidermal growth factor receptor ligands (EGFR) are involved in tumor-associated osteolysis, we hypothesize that the EGFR ligand amphiregulin (AREG) can be delivered by MM-derived exosomes and participate in MM-induced osteoclastogenesis. Methods: Exosomes were isolated from the conditioned medium of MM1.S cell line and from bone marrow (BM) plasma samples of MM patients. The murine cell line RAW264.7 and primary human CD14 + cells were used as osteoclast (OC) sources. Results: We found that AREG was specifically enriched in exosomes from MM samples and that exosomes-derived AREG led to the activation of EGFR in pre-OC, as showed by the increase of mRNA expression of its downstream SNAIL in both RAW264.7 and CD14 + cells. The presence of neutralizing anti-AREG monoclonal antibody (mAb) reverted this effect. Consequently, we showed that the effect of MM-derived exosomes on osteoclast differentiation was inhibited by the pre-treatment of exosomes with anti-AREG mAb. In addition, we demonstrated the ability of MM-derived AREG-enriched exosomes to be internalized into human mesenchymal stromal cells (MSCs) blocking osteoblast (OB) differentiation, increasing MM cell adhesion and the release of the pro-osteoclastogenic cytokine interleukin-8 (IL8). Accordingly, anti-AREG mAb inhibited the release of IL8 by MSCs suggesting that both direct and indirect effects are responsible for AREG-enriched exosomes involvement on MM-induced osteoclastogenesis. Conclusions: In conclusion, our data indicate that AREG is packed into MM-derived exosomes and implicated in OC differentiation through an indirect mechanism mediated by OBs

po 146 multiple myeloma derived exosomes carry amphiregulin and are responsible for the uncoupled bone remodelling

Introduction Multiple myeloma (MM) is a hematologic malignancy associated with osteolytic bone disease caused by the perturbation of the functional balance between bone resorption and bone formation. Exosomes, nanosize lipoproteic structures, have been recently recognised as a new mechanism of cell to cell communication during tumour growth and progression. We have previously shown that MM-exosomes are involved in osteolytic lesions but the underlying mechanism is still understood. We hypothesise that the epidermal growth factor receptor ligand Amphiregulin (AREG) can be delivered by multiple myeloma-derived exosomes and participate in modulating the response of the bone microenvironment to the tumour. Material and methods Exosomes were isolated from the conditioned medium of MM1 cell line and from BM plasma samples of patients. In order to test whether MM-exosomes could affect osteoclastogenesis through the activation of the EGFR pathway, primary CD14 +monocytes and a murine cell line (RAW264.7) were used as osteoclast (OC) models. Cells were treated with exosomes from both MM1 and plasma samples, pre-treated or not with anti-AREG neutralising antibodies and OC specific markers were measured. In addition, to further explore whether exosomes were able to promote osteoclastogenesis by affecting mesenchymal stem cells, hTERT-MSC were treated with exosomes; the conditioned medium were collected to measure the secretion of IL8 and to stimulate primary CD14 +monocytes. Results and discussions We found that AREG was specifically enriched in exosome samples, leading to the activation of EGFR in pre-OC. In addition we showed a significant increase of the expression of the OC markers Cathepsin K, Matrix Metalloproteinases 9 and Tartrate-resistant Acid Phosphatase in RAW 264.7 and CD14 +cells after treatment with MM-derived exosomes as compared to the control. The effects of MM-derived exosomes on OC activation were significantly abrogated by exosome pre-treatment with anti-AREG neutralising Ab directly on pre-osteoclast cells and indirectly by inhibiting IL8 release in MSC. Conclusion Taken together our data indicate that MM-derived exosomes are responsible for the uncoupled bone remodelling, affecting directly osteoclast function and promoting IL8 release from mesenchymal stromal cells. In this context, AREG packed into MM-derived exosomes, represents a potential new player in MM-induced bone resorption

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe

Infected pancreatic necrosis: outcomes and clinical predictors of mortality. A post hoc analysis of the MANCTRA-1 international study

: The identification of high-risk patients in the early stages of infected pancreatic necrosis (IPN) is critical, because it could help the clinicians to adopt more effective management strategies. We conducted a post hoc analysis of the MANCTRA-1 international study to assess the association between clinical risk factors and mortality among adult patients with IPN. Univariable and multivariable logistic regression models were used to identify prognostic factors of mortality. We identified 247 consecutive patients with IPN hospitalised between January 2019 and December 2020. History of uncontrolled arterial hypertension (p = 0.032; 95% CI 1.135-15.882; aOR 4.245), qSOFA (p = 0.005; 95% CI 1.359-5.879; aOR 2.828), renal failure (p = 0.022; 95% CI 1.138-5.442; aOR 2.489), and haemodynamic failure (p = 0.018; 95% CI 1.184-5.978; aOR 2.661), were identified as independent predictors of mortality in IPN patients. Cholangitis (p = 0.003; 95% CI 1.598-9.930; aOR 3.983), abdominal compartment syndrome (p = 0.032; 95% CI 1.090-6.967; aOR 2.735), and gastrointestinal/intra-abdominal bleeding (p = 0.009; 95% CI 1.286-5.712; aOR 2.710) were independently associated with the risk of mortality. Upfront open surgical necrosectomy was strongly associated with the risk of mortality (p < 0.001; 95% CI 1.912-7.442; aOR 3.772), whereas endoscopic drainage of pancreatic necrosis (p = 0.018; 95% CI 0.138-0.834; aOR 0.339) and enteral nutrition (p = 0.003; 95% CI 0.143-0.716; aOR 0.320) were found as protective factors. Organ failure, acute cholangitis, and upfront open surgical necrosectomy were the most significant predictors of mortality. Our study confirmed that, even in a subgroup of particularly ill patients such as those with IPN, upfront open surgery should be avoided as much as possible. Study protocol registered in ClinicalTrials.Gov (I.D. Number NCT04747990)